/
NBIX
$169.55-$0.46 (-0.27%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$16.9B
101M shares
52-week range
$122.14 – $171.50
96% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.25%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$72.08
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $451.2M | $788.1M | $1.05B | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
| Cost of revenue | $4.9M | $7.4M | $10.1M | $14.3M | $23.2M | $39.7M | $34.0M | $52.1M |
| Gross profit | $446.3M | $780.7M | $1.04B | $1.12B | $1.47B | $1.85B | $2.32B | $2.81B |
| Gross margin | 98.9% | 99.1% | 99.0% | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% |
| R&D | $155.8M | $200.0M | $275.0M | $328.1M | $463.8M | $565.0M | $731.1M | $1.02B |
| Operating income | $36.8M | $72.3M | $163.0M | $102.5M | $249.0M | $250.9M | $570.5M | $619.1M |
| EBITDA | $56.3M | $85.9M | $148.1M | $138.1M | $236.6M | $416.1M | $639.7M | $666.6M |
| Net income | $21.1M | $37.0M | $407.3M | $89.6M | $154.5M | $249.7M | $341.3M | $478.6M |
| Net margin | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| EPS (diluted) | 0.22 | 0.39 | 4.16 | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3.7B | $7.72 | $6.74–$9.65 | 13 |
| 2027 | $4.3B | $9.68 | $7.66–$11.16 | 12 |
| 2028 | $4.9B | $12.15 | $7.00–$21.36 | 16 |
| 2029 | $5.1B | $13.68 | $11.66–$16.10 | 14 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$429.38
Price
$169.54
Implied upside
+153%
Peer comparison
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
www.neurocrine.com- Employees
- 2,000
- IPO / List date
- May 23, 1996
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds NBIX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,418,897 | $318.7M |
| Bridgewater Associatesas of 2026-03-31 | 148,141 | $19.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NBIX yet.
